Huiqiang Huang

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Matthew Ku, Mark P. Hertzberg, Huiqiang Huang et al. · The Lancet · 2024 · 142 citations

Medicine, Hematology, Oncology +15

Comparison of Quantitative and Qualitative Tests for Glucose-6-Phosphate Dehydrogenase Deficiency

Nicole LaRue, Maria Kahn, Marjorie F. Murray et al. · American Journal of Tropical Medicine and Hygiene · 2014 · 112 citations · Full text

Medicine, Hematology, Pharmacology +17

First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: An updated analysis with long-term follow-up

Liang Wang, Zhihui Wang, X Y Chen et al. · Oncology Letters · 2015 · 59 citations · Full text

Medicine, Oncology, Radiation Oncology +13

A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors

Xubin Lin, Huiqiang Huang, Su Li et al. · Cancer Biology & Therapy · 2007 · 37 citations · Full text

Medicine, Oncology, Pharmacology +13

Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study

Yan Gao, Haixia He, Xue‐Ping Li et al. · Signal Transduction and Targeted Therapy · 2024 · 34 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16